GSK Stock Recent News
GSK LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138757&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138671&wire=1 or contact Joseph E. Levi, Esq.
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and pediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary tract infections (uUTIs) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. Discovered by GSK scientists.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138641&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138625&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138612&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138579&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138485&wire=1 or contact Joseph E. Levi, Esq.
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of dementia.
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=138384&wire=1 or contact Joseph E. Levi, Esq.